The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 34, No. 4, pp. 487-494. DOI 10.1345/aph.19183
© 2000 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Battaglia, A.
Right arrow Articles by Hagmeyer, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Battaglia, A.
Right arrow Articles by Hagmeyer, K.

Research Articles

Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection

AM Battaglia and KO Hagmeyer

OBJECTIVE: To review and critique the medical literature regarding the combination of interferon and ribavirin in the initial treatment of chronic hepatitis C virus (HCV) infection. DATA SOURCES: A MEDLINE search (January 1966-June 1999) was conducted to identify human clinical trials regarding the combination of interferon and ribavirin therapy for the initial treatment of chronic HCV. Bibliographies were reviewed for relevant literature. STUDY SELECTION: Clinical trials of combination interferon and ribavirin for the treatment of chronic HCV in interferon-naive adults were reviewed. DATA SYNTHESIS: The combination of ribavirin and interferon in the treatment of chronic HCV has been beneficial in patients who are interferon-naive. Patients with predictors of poor response, such as baseline cirrhosis, male gender, age >40 years, high baseline viral loads (>2 x 10(6) copies/mL), and genotype 1 respond better to combination treatment when compared with those who receive interferon monotherapy. Patients with genotype 1 and/or high viral loads may benefit most from 48 weeks of combination therapy; however, adverse effects are of greater concern in these patients. Monitoring can limit these complications. CONCLUSIONS: Combination therapy is effective in the treatment of interferon-naive patients with chronic HCV infection. Patients should be evaluated for duration of treatment with combination therapy by determination of predictors of response. Further trials are needed to more closely evaluate the duration of treatment and to determine the best patient population to receive combination therapy.


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
C.-Q. Wang, Y. Li, S. D. Douglas, X. Wang, D. S. Metzger, T. Zhang, and W.-Z. Ho
Morphine Withdrawal Enhances Hepatitis C Virus Replicon Expression
Am. J. Pathol., November 1, 2005; 167(5): 1333 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. K. Geiss, V. S. Carter, Y. He, B. K. Kwieciszewski, T. Holzman, M. J. Korth, C. A. Lazaro, N. Fausto, R. E. Bumgarner, and M. G. Katze
Gene Expression Profiling of the Cellular Transcriptional Network Regulated by Alpha/Beta Interferon and Its Partial Attenuation by the Hepatitis C Virus Nonstructural 5A Protein
J. Virol., June 1, 2003; 77(11): 6367 - 6375.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2000 by Harvey Whitney Books Company.